<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736758</url>
  </required_header>
  <id_info>
    <org_study_id>GP681-202002</org_study_id>
    <nct_id>NCT04736758</nct_id>
  </id_info>
  <brief_title>A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to&#xD;
      evaluate the antiviral effects of high and low doses of GP681 tablets, and explore the&#xD;
      optimal dose for phase III clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to alleviation of influenza symptoms</measure>
    <time_frame>Day 15</time_frame>
    <description>Defined as the time from the start of treatment until the patient's body temperature returns to normal and all 7 flu symptoms (cough, sore throat, headache, nasal congestion, fever or chills, muscle or joint pain, fatigue) have alleviated (scoring 0 or 1 point) .</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GP681 tablet 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP681 tablet 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the GP681 tablet 40mg group is treated with GP681 tablet 20mg orally once with 240mL water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the Placebo group is treated with GP681 Simulant orally once with 240mL water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP681 tablet</intervention_name>
    <description>influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.</description>
    <arm_group_label>GP681 tablet 20mg</arm_group_label>
    <arm_group_label>GP681 tablet 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP681 Simulant</intervention_name>
    <description>influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive Influenza rapid antigen test;&#xD;
&#xD;
          -  Fever (axillary temperature ≥37.3℃) or the axillary temperature ≥37.3℃ after taking&#xD;
             the medicine for more than 4 hours;&#xD;
&#xD;
          -  At least one systemic symptom and respiratory symptom related to a moderate or above&#xD;
             influenza virus infection:&#xD;
&#xD;
               1. Systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue;&#xD;
&#xD;
               2. Respiratory system symptoms: cough, sore throat, nasal congestion.&#xD;
&#xD;
          -  Time of disease symptoms ≤48h&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as severe influenza patient ;&#xD;
&#xD;
          -  Known history of dysphagia or any gastrointestinal disease that affects drug&#xD;
             absorption (including but not limited to reflux esophagitis, chronic diarrhea,&#xD;
             inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome,&#xD;
             stomach After subtotal resection, etc.);&#xD;
&#xD;
          -  Have used anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir,&#xD;
             abidol, baloxavir dipivoxil, amantadine, or diamond) within 2 weeks before screening&#xD;
             Ethylamine, etc.);&#xD;
&#xD;
          -  Acute respiratory infections, otitis media, sinusitis or other infectious diseases&#xD;
             such as bronchitis, pneumonia, tuberculosis, etc. occurred within 2 weeks before&#xD;
             screening, and are in the acute stage;&#xD;
&#xD;
          -  Patients who also suffer from bacterial or viral infections and need systemic&#xD;
             antibacterial or antiviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Cao, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoping Liu</last_name>
    <phone>84206250</phone>
    <phone_ext>10</phone_ext>
    <email>zryyec@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang</last_name>
      <phone>13707089183</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

